• Corpus ID: 11055072

Management of erectile dysfunction.

  title={Management of erectile dysfunction.},
  author={David J Ralph},
  journal={International journal of STD \& AIDS},
  volume={10 3},
  • D. Ralph
  • Published 1999
  • Psychology, Medicine
  • International journal of STD & AIDS
AETIOLOGY ED is a hidden condition with patients rarely volunteering information due to a variety of factors including embarrassment and a feeling that little can be done.1,2,4 It is associated with significant morbidity and can impair the patient’s quality of life. Depression, increased anxiety and poor self-esteem may also be associated with this condition.4 Risk factors for ED are included in Table 1. 

Tables from this paper

Role of Stress in Erectile Dysfunction: A Review
The most commonly explained pathophysiology is vascular disease, which is more common in men above 40 years of age.
Erectile dysfunction. A guide to diagnosis and management.
The mechanisms of normal erectile function and dysfunction and the assessment and management of ED are discussed and the success of currently available and newly emerging oral agents has revolutionised the management.
Evaluation of Sexual Dysfunction in Patients with Rheumatoid Arthritis
This descriptive-analytical study was conducted in the first 6 months of 2015 in Qom city and data collection tool was demographic characteristics questionnaire, Female Sexual Function Index, International Index of Erectile Function, and checklist of patient information, clinical examination, and laboratory data.
Modulating Erectile Dysfunction
  • S. Chaudhry
  • Medicine
    Annals of Geriatric Education and Medical Sciences
  • 2020
The global Erectile Dysfunction Drugs Market size was valued USD 1.65 billion in 2016 and is expected to reach a valuation of USD 2.95 billion at a CAGR of 6.5% by 2023, as per Market Research Future.
Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999
To examine the safety of sildenafil, the first of the phosphodiesterase type 5 inhibitors licensed for the treatment of male erectile dysfunction (ED), as used in general medical practice in England,
The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes.
Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction
As the world’s older population increases, it is estimated that the prevalence of ED will double from 152 million men in 1995 to 322 millionMen in 2025, indicating a dire need to reevaluate current ED therapeutic strategies.
Diagnosis and management of erectile dysfunction in the primary care setting
An update on ED screening and management focusing on the use of PDE‐5 inhibitor therapy in the primary care setting is provided and clinical efficacy parameters with regard to recent results from clinical trials are discussed.
Erectile Dysfunction Among Men Attending Surgical Outpatients Department in a Tertiary Hospital in South-Western Nigeria
The number of men with erectile dysfunction managed in the tertiary hospital in Ibadan southwestern Nigeria is very low though the outcome of treatment is within acceptable range, and increase public enlightenment may encourage increase hospital patronage and access to the available treatments.
Erectile dysfunction in common neurological conditions: A narrative review.
The physiology, pathophysiology, diagnosis, and treatment of ED in multiple peripheral and central neurologic conditions, as well as for future research, are discussed.